At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,686 enrolled
Drug / intervention
Ubrogepant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
In Brief
A Phase 3 clinical trial evaluating Ubrogepant and Placebo-matching Ubrogepant for Migraine, With or Without Aura. Completed, enrolled 1,686 participants across 109 sites.
Detailed Summary
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, With or Without Aura
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartAug 2016
Primary CompletionJan 2018
Study CompletionFeb 2018
TodayJul 2026
First PostedAug 16, 2016
Enrollment StartAug 26, 2016
Primary CompletionJan 25, 2018
Study CompletionFeb 26, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.9 years ago
Interventions
Ubrogepantdrug
Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Placebo-matching Ubrogepantdrug
Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.